Gabriel Ortega

Unconventional DNA architecture in a dopamine-bound aptamer complex biorxiv.org/content/10.110… #biorxiv_biochem

The first two lines of this paper illustrate quite how important this discovery is: “Approximately half the worldwide population is at risk for dengue. No antiviral prophylaxis or treatment options are available.”

¿Qué son y para qué sirven los biosensores? Aquí hablo de ello en #BioEnredados el podcast de divulgación científica de @CICbioGUNE Enjoy!

Predicting protein-protein interactions in the human proteome | Science science.org/doi/10.1126/sc…

A huge honor to be recognized as one of the 2024 Rising Stars in Measurement Science @ACSPublications @KTHuniversity @UCAM @UCAM_Investiga @UCAM_SENS Celebrating the 2024 Rising Stars in Measurement Science | ACS Measurement Science Au pubs.acs.org/doi/10.1021/ac…

Very excited to host @MarianaMedinaS6,@Ikerbasque researcher at @nanoGUNE, as part of our research seminars at @CICbioGUNE Amazing research on microrobots, fertility treatments, and much more!

@YFichou @ERC_Research @CNRS @ERCGrantees Come to bluesky!

Misinformation has never spread so easily on X, often serving radical political endeavors. As scientists who establish truth based on facts, we cannot support that. I encourage my colleagues and institution @ERC_Research @CNRS @ERCGrantees to think of the impact of X worldwide.

Por primera vez, el trabajo del personal investigador de Euskadi supera las 8.000 publicaciones científicas. Cerca de 23.000 personas se dedican a la investigación en Euskadi. @Ikerbasque @CICbioGUNE @biocrucesHRI @biogipuzkoa @Uhandrea

Has protein binder design been solved? We analyze the results of our protein design competition where 130 designers created binders for EGFR. With a 5x improvement in success rates and some designs outperforming clinical antibodies, we explore what worked, what didn't, and what this means for the future of protein engineering. Link ⬇️

#bioGUNE_Research | 🔍 Researchers discover postal code that allows proteins to hitch a ride around the body 🧬 An international research team @OttawaHospital, #CICbioGUNE @brta_eus & @CRGenomica 🧾 @ScienceAdvances 🎉 Congratulations! 🔗 ow.ly/eqEi50Urxka

La UCAM, portada de la revista ‘Analytical Chemistry’ por sus avances en sensores murciadiario.com/articulo/forma… a través de @Murdiario @UCAM @UCAM_SENS 📰Suscríbete a nuestro Boletín diario de Noticias: murciadiario.com/seccion/newsle…

#bioGUNE_News | 🚀 €2M for cancer research at #CICbioGUNE @brta_eus #CICbioGUNE has received €2M from @ContraCancerEs @contracancerINV to advance #PreMetaCan, exploring metabolism’s role in cancer and developing personalized therapies 🔗ow.ly/FFJu50Unj9e

PROTEIN DESIGN COMPETITION ROUND 2 The long awaited results are here -- and they don’t disappoint! 📈 We doubled the number of proteins we tested in our lab from 200 to 400! 🧬 Out of those 400 proteins, 378 expressed (95% expression rate!) 🚀 Out of those 378 expressed proteins, 53 did successfully bind the target protein EGFR (that’s a 14% success rate, more than 5x of the success rate of the previous round just 2 months ago!) 💪 The best binders reached single-digit nanomolar affinities which is within the range of the commercially sold Cetuximab antibody by Merck 😎 30 out of 130 protein designers managed to design at least one binding protein More details ⬇️

Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeutic discovery. We introduce JAM, an AI system we’ve developed to design de novo antibodies with good affinities, early stage developability, and function. We’re seeing success across a range of soluble and hard-to-drug membrane proteins including a Claudin and a GPCR. We’ve extensively tested these designs in our wet lab and included detailed data and controls, providing the first clear demonstration of how de novo design could expand the scope and efficiency of therapeutic antibody discovery. 🧵 Technical report: …bla-public.s3.us-east-1.amazonaws.com/2024_Nabla_JAM… Blog: nabla.bio/news/denovo

Thrilled to announce Boltz-1, the first open-source and commercially available model to achieve AlphaFold3-level accuracy on biomolecular structure prediction! An exciting collaboration with @jeremyWohlwend, @pas_saro and an amazing team at MIT and Genesis Therapeutics. A thread!

- @CICbioGUNE recibe financiación de @CaixaResearch para avanzar en una terapia #innovadora contra la malaria tinyurl.com/2s3bevf7

📢 We are hiring, please RT! Join us as a #PhDstudent in the @ERC_Research project #DORMATRIX, modeling #breastcancer #dormancy with novel #biomaterials. Bioengineers, (bio)chemists or similar. @biogipuzkoa @Ikerbasque. More info & apply until 31/12👉bit.ly/4hM4xCr

🎉We're celebrating! @Ikerbasque Prof Luis @LizMarzan_Lab, @EmatSaraBals & @Kotov_group awarded a 9 M€ ERC Synergy Grant! CHIRAL-PRO aims to design nanoparticles that recognize proteins combining AI and nanoscience 👉cicbiomagune.es/node/42513 @uvigo @UAntwerpen @UMich @CIBERBBN

‼️ Oscar Millet delivered the final plenary talk of the day on metabolic syndrome investigated through NMR metabolomics. #VLAMPS